Geron (NASDAQ:GERN) Stock Price Down 5.2% – Time to Sell?

Shares of Geron Corporation (NASDAQ:GERN) traded down 5.2% during trading on Friday . The stock traded as low as $1.46 and last traded at $1.4550. Approximately 2,265,197 shares were traded during trading, a decline of 85% from the average session volume of 14,869,412 shares. The stock had previously closed at $1.5350.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Trading Down 5.2%

The company has a 50 day moving average of $1.37 and a 200 day moving average of $1.47. The firm has a market cap of $934.79 million, a P/E ratio of -13.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 5.16 and a current ratio of 6.91.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The business had revenue of $57.48 million during the quarter, compared to analyst estimates of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. Analysts predict that Geron Corporation will post -0.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Geron

Large investors have recently bought and sold shares of the business. 55 North Private Wealth LLC acquired a new position in Geron during the fourth quarter worth $29,000. LCM Capital Management Inc lifted its position in shares of Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 10,000 shares during the last quarter. Vistica Wealth Advisors LLC bought a new position in shares of Geron in the 4th quarter valued at approximately $33,000. Hsbc Holdings PLC bought a new stake in Geron during the first quarter worth approximately $33,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 24,410 shares during the period. 73.71% of the stock is currently owned by institutional investors.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.